Cargando…

Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia

OBJECTIVE: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Andy Sing Ong, Leong, Tze Shin, Ong, Joyce Hong Ling, Goh, Adrian, Chew, Lee Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334073/
https://www.ncbi.nlm.nih.gov/pubmed/36974524
http://dx.doi.org/10.31557/APJCP.2023.24.3.733
_version_ 1785070788854939648
author Tang, Andy Sing Ong
Leong, Tze Shin
Ong, Joyce Hong Ling
Goh, Adrian
Chew, Lee Ping
author_facet Tang, Andy Sing Ong
Leong, Tze Shin
Ong, Joyce Hong Ling
Goh, Adrian
Chew, Lee Ping
author_sort Tang, Andy Sing Ong
collection PubMed
description OBJECTIVE: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Health (MOH) hospitals in Sarawak, Malaysia. METHODS: The estimation of treatment cost was a planned analysis of the Real World Evidence (RWE) study which included retrospective chart review of adult MF patients treated in Sarawak General, Sibu, Bintulu and Miri Hospitals. The study was approved by Sarawak General Hospital HRRC and MREC. The current study was conducted to estimate the cost of out-patient visits, hospitalisation, transfusion and medication from the perspective of MOH. Out-patient visits and hospitalisation costs were calculated using current unit costs for full fee-paying charges of MOH hospitals. Transfusion costs were estimated for packed cell and platelet transfusions. Medication costs were calculated using drug prices from IQVIA database for MOH hospital sub-sector in 2021. Unit costs were standardised to index year of 2021. RESULT: Data from 63 patients was available for analysis. Mean annual health resource utilisation (HRU) was 6.13 clinic visits, 9.47 days of hospitalisation and 1.61 transfusions per patient per year. Mean HRU cost was RM23,320 (USD5,217) per patient per year, comprised of RM19,122 (USD4,278) in drug costs, RM3,030 (USD678) for hospitalisation, RM799 (USD178) for transfusions and RM368 (USD82) for outpatient cost. CONCLUSION: The present analysis suggests that medication and hospitalisation were the main drivers of costs for MF treatment in Sarawak MOH hospitals. This study provides the first RWE estimate of the cost of MF in Malaysia and may provide insight into unmet clinical needs and a guide for further health economic research into the treatment of MF.
format Online
Article
Text
id pubmed-10334073
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-103340732023-07-12 Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia Tang, Andy Sing Ong Leong, Tze Shin Ong, Joyce Hong Ling Goh, Adrian Chew, Lee Ping Asian Pac J Cancer Prev Short Communication OBJECTIVE: Primary myelofibrosis is a rare type of myeloproliferative neoplasm with an annual incidence rate of 0.47 per 100,000. A retrospective, observational study was conducted to determine the disease evolution and costs of treatment for myelofibrosis (MF) patients managed in 4 Ministry of Health (MOH) hospitals in Sarawak, Malaysia. METHODS: The estimation of treatment cost was a planned analysis of the Real World Evidence (RWE) study which included retrospective chart review of adult MF patients treated in Sarawak General, Sibu, Bintulu and Miri Hospitals. The study was approved by Sarawak General Hospital HRRC and MREC. The current study was conducted to estimate the cost of out-patient visits, hospitalisation, transfusion and medication from the perspective of MOH. Out-patient visits and hospitalisation costs were calculated using current unit costs for full fee-paying charges of MOH hospitals. Transfusion costs were estimated for packed cell and platelet transfusions. Medication costs were calculated using drug prices from IQVIA database for MOH hospital sub-sector in 2021. Unit costs were standardised to index year of 2021. RESULT: Data from 63 patients was available for analysis. Mean annual health resource utilisation (HRU) was 6.13 clinic visits, 9.47 days of hospitalisation and 1.61 transfusions per patient per year. Mean HRU cost was RM23,320 (USD5,217) per patient per year, comprised of RM19,122 (USD4,278) in drug costs, RM3,030 (USD678) for hospitalisation, RM799 (USD178) for transfusions and RM368 (USD82) for outpatient cost. CONCLUSION: The present analysis suggests that medication and hospitalisation were the main drivers of costs for MF treatment in Sarawak MOH hospitals. This study provides the first RWE estimate of the cost of MF in Malaysia and may provide insight into unmet clinical needs and a guide for further health economic research into the treatment of MF. West Asia Organization for Cancer Prevention 2023 /pmc/articles/PMC10334073/ /pubmed/36974524 http://dx.doi.org/10.31557/APJCP.2023.24.3.733 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Short Communication
Tang, Andy Sing Ong
Leong, Tze Shin
Ong, Joyce Hong Ling
Goh, Adrian
Chew, Lee Ping
Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
title Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
title_full Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
title_fullStr Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
title_full_unstemmed Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
title_short Cost of Treatment for Myelofibrosis Patients in Ministry of Health Hospitals in Sarawak, Malaysia
title_sort cost of treatment for myelofibrosis patients in ministry of health hospitals in sarawak, malaysia
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334073/
https://www.ncbi.nlm.nih.gov/pubmed/36974524
http://dx.doi.org/10.31557/APJCP.2023.24.3.733
work_keys_str_mv AT tangandysingong costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia
AT leongtzeshin costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia
AT ongjoycehongling costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia
AT gohadrian costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia
AT chewleeping costoftreatmentformyelofibrosispatientsinministryofhealthhospitalsinsarawakmalaysia